Hercules Capital (HTGC) Earnings Growth Slowdown Tests Bullish Margin Expansion Narrative

Hercules Capital, Inc.

Hercules Capital, Inc.

HTGC

0.00

How Hercules Capital's Latest Numbers Set the Stage for the Current Debate

Hercules Capital (HTGC) has opened 2026 with Q1 revenue of US$141.5 million and basic EPS of US$0.23, alongside trailing twelve month revenue of US$554.5 million and EPS of US$1.83 that reflect the strong 49.4% earnings growth recorded over the past year. Over recent quarters the company has seen revenue move from US$119.5 million in Q1 2025 to US$141.5 million in Q1 2026, with quarterly EPS ranging from US$0.29 to US$0.66 across 2025 before settling at US$0.23 this quarter, while trailing net profit margins improved from 44.8% to 59.4% in the period covered. With that backdrop of higher margins and forecast revenue and earnings growth in the mid single digits, this set of results gives investors plenty to weigh up around the balance between growth and profitability.

See our full analysis for Hercules Capital.

The next step is to set these results against the widely followed Hercules Capital narratives to see where the numbers support the story investors know and where those stories might need an update.

NYSE:HTGC Earnings & Revenue History as at May 2026
NYSE:HTGC Earnings & Revenue History as at May 2026

59.4% margins meet mixed EPS trend

  • Over the last 12 months Hercules converted US$554.5 million of revenue into US$329.2 million of net income, a 59.4% net margin, even as quarterly basic EPS moved between US$0.29 and US$0.66 in 2025, then came in at about US$0.23 in Q1 2026.
  • Bulls point to this combination of high trailing margins and prior 49.4% earnings growth as support for stronger future returns. However, the data also shows forecasts of roughly 6.3% annual earnings growth, which is slower than the earlier pace.
    • On the bullish side, the view is that a high first lien focus and over US$1b of liquidity can help sustain profitability even if EPS moves around from quarter to quarter.
    • Set against that, the more moderate ~6% earnings and revenue growth assumptions in the forecasts are less aggressive than some optimistic margin expansion scenarios. As a result, the bullish story meets a more grounded growth path in the numbers.
On these figures, many investors will want to see whether the higher margin profile really lines up with the more optimistic long term story for Hercules Capital, and how that squares with the forecast growth path in the coming years. 🐂 Hercules Capital Bull Case

Valuation gap vs DCF and 9.2x P/E

  • With the share price around US$16.44, Hercules is shown on a P/E of 9.2x, trading below a DCF fair value of about US$25.87 and also below peer and US Capital Markets industry averages of 17.1x and 42.8x respectively.
  • Bears focus on risks around leverage and cash coverage, arguing that a lower multiple is justified, while the current 59.4% net margin and 49.4% trailing earnings growth tell a different story.
    • Critics highlight that debt is not well covered by operating cash flow and that an 11.44% dividend is not well covered by free cash flow, which can pressure equity holders if conditions tighten.
    • Against that cautious view, the combination of high margins, trailing earnings growth and a P/E that sits well below peers is what value oriented investors use to question whether the bearish focus on balance sheet risk fully explains the discount.
Skeptical investors often compare these valuation markers with balance sheet pressures to judge whether Hercules is simply cheap for a reason or priced below what its recent profitability would suggest. 🐻 Hercules Capital Bear Case

Growth forecasts cool after 49.4% earnings jump

  • Trailing earnings grew 49.4% over the past year, yet the current dataset shows revenue expected to grow about 6.6% per year and earnings about 6.3% per year, both below the cited US market growth rates of 11.4% for revenue and 16.4% for earnings.
  • Analysts' consensus narrative talks about strong demand from tech and life sciences borrowers and better operating efficiency, while the more modest ~6% growth outlook keeps expectations in check.
    • What stands out is that even with expanding exposure to technology and life sciences lending, projected growth rates are lower than the broader market figures provided, so the story is more about steady compounding than rapid expansion.
    • At the same time, higher expenses from platform growth and higher interest costs on new funding are cited as possible drags on future margins, which fits with the idea that growth may be slower than the recent 49.4% earnings jump suggests.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Hercules Capital on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With the mix of strong margins, balance sheet questions and cooling growth forecasts, opinion on Hercules Capital is clearly split. Check the full numbers, weigh the trade offs and see how the 4 key rewards and 2 important warning signs fits your own conclusion.

Explore Alternatives

Hercules Capital combines high trailing margins with slower forecast growth, mixed EPS trends and concerns over debt coverage and dividend sustainability, which may limit comfort on risk.

If those balance sheet and cash flow concerns make you uneasy, shift your focus toward companies in the solid balance sheet and fundamentals stocks screener (45 results) that aim to pair fundamentals with stronger financial resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.